Grifols reports Q4 adjusted EBITDA of EUR 526M, up 19% from last year

Reports Q4 revenue of EUR 1.976B, up 13.6% at constant currency. Nacho Abia, Chief Executive Officer, commented, “Grifols (GRFS) delivered an all-time high performance, achieving its 2024 commitments and goals thanks to the team’s unwavering focus and dedication during what was a challenging year. Their hard work and dedication to patients are apparent across the company, from a re-energized Biopharma business to completing innovation milestones, to the strategic alliance with Haier Group in support of deleveraging. Our actions have built clear momentum and position us for sustainable, profitable growth into 2025 and beyond.”